Agenus to Participate in September Investor Conferences

Rhea-AI Summary

Agenus (NASDAQ: AGEN), a clinical-stage immuno-oncology company, recently announced participation in two upcoming conferences. Jennifer Buell, PhD, President and COO, will present at the H.C. Wainwright 23rd Annual Global Investment Conference on-demand starting September 13, 2021. Additionally, she will speak at the Baird 2021 Global Healthcare Conference on September 15, 2021, from 4:20 p.m. to 4:50 p.m. ET. A webcast replay for the Baird conference will be available on the company's website. Agenus focuses on therapies that utilize the body’s immune system to combat cancer.

LEXINGTON, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Jennifer Buell, PhD, President and COO of Agenus, will participate in the following upcoming conferences:

• H.C. Wainwright 23^rd Annual Global Investment Conference presentation will be available on-demand from Monday, September 13, 2021, starting at 7:00 a.m. ET.
• Baird 2021 Global Healthcare Conference presentation on Wednesday, September 15, 2021 from 4:20 p.m. to 4:50 p.m. ET.

A webcast and replay for the Baird 2021 Global Healthcare Conference may be accessed on the company's website at https://investor.agenusbio.com/events-and-presentations.

About Agenus

Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its MiNK Therapeutics subsidiary), adjuvants, and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter.

Contact
Agenus Investor Relations
Jan Medina, CFA
Agenus
781-674-4490
Jan.Medina@agenusbio.com

Agenus Media Relations
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com

FAQ

What conferences will Agenus participate in September 2021?

Agenus will participate in the H.C. Wainwright 23rd Annual Global Investment Conference and the Baird 2021 Global Healthcare Conference.

What is the date and time of the Baird 2021 Global Healthcare Conference presentation?

The Baird presentation is scheduled for September 15, 2021, from 4:20 p.m. to 4:50 p.m. ET.

Where can I access the webcast for Agenus' Baird conference presentation?

The webcast for the Baird 2021 Global Healthcare Conference can be accessed on Agenus' website.

Who is presenting for Agenus at the upcoming conferences?

Jennifer Buell, PhD, President and COO of Agenus, will be the presenter.

What is the focus of Agenus as a company?

Agenus focuses on developing immuno-oncology therapies that engage the immune system to fight cancer.